The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties will launch a new Antibody- ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

A patient-led study examines the potential of extended Paxlovid courses for Long COVID relief, documenting varied outcomes ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Abrupt end of Pfizer's hemophilia A gene therapy deal with Sangamo is the latest in a line of flip-flops between the big drug ...